Stock Mover of the Day: Echo Therapeutics Inc (OTCMKTS:ECTE) Shifting Institutional Investors Sentiment

November 18, 2016 - By Adrian Mccoy   ·   0 Comments

Stock Mover of the Day: Echo Therapeutics Inc (OTCMKTS:ECTE) Shifting Institutional Investors Sentiment

Sentiment for Echo Therapeutics Inc (OTCMKTS:ECTE)

Echo Therapeutics Inc (OTCMKTS:ECTE) institutional sentiment decreased to 0 in 2016 Q2. Its down -1.60, from 1.6 in 2016Q1. The ratio has dropped, as 8 hedge funds increased and opened new equity positions, while 5 sold and decreased their holdings in Echo Therapeutics Inc. The hedge funds in our partner’s database now hold: 621,792 shares, down from 1.40 million shares in 2016Q1. Also, the number of hedge funds holding Echo Therapeutics Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 3 Increased: 3 New Position: 5.

Echo Therapeutics, Inc. is a medical device company. The company has a market cap of $4.27 million. The Firm is engaged in developing a non-invasive, wireless continuous glucose monitoring system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. It currently has negative earnings. The Firm operates through the development of transdermal skin permeation and diagnostic medical devices segment.

About 1,460 shares traded hands. Echo Therapeutics Inc (OTCMKTS:ECTE) has declined 69.77% since April 18, 2016 and is downtrending. It has underperformed by 74.20% the S&P500.

Analysts await Echo Therapeutics Inc (OTCMKTS:ECTE) to report earnings on November, 21.

According to Zacks Investment Research, “Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, develops a non-invasive and wireless transdermal continuous glucose monitoring system for people with diabetes and for use in hospital critical care units in the United States. Its Symphony transdermal continuous glucose monitoring System is a non-invasive, wireless, designed to provide reliable, on-demand blood glucose data conveniently, continuously and cost-effectively. The company is based in Franklin, Massachusetts.”

Bank Of America Corp De holds 0% of its portfolio in Echo Therapeutics Inc for 74 shares. Bb&T Corp owns 12,000 shares or 0% of their US portfolio. Moreover, Blackrock Fund Advisors has 0% invested in the company for 1,709 shares. The Illinois-based Citadel Advisors Llc has invested 0% in the stock. Deutsche Bank Ag, a Germany-based fund reported 10,158 shares.#img1#

ECTE Company Profile

Echo Therapeutics, Inc., incorporated on October 10, 2007, is a medical device company. The Firm is engaged in developing a non-invasive, wireless continuous glucose monitoring (CGM) system with use in the wearable-health consumer market, diabetes outpatient market and in the hospital setting. The Firm operates through the development of transdermal skin permeation and diagnostic medical devices segment. The Firm has also developed its needle-free skin preparation device as a platform technology that allows for enhanced skin permeation enabling extraction of analytes, such as glucose, enhanced delivery of topical pharmaceuticals and other applications.

More notable recent Echo Therapeutics Inc (OTCMKTS:ECTE) news were published by: Valuewalk.com which released: “Echo Therapeutics Separation Agreement With Scott Hollander” on September 26, 2016, also Prnewswire.com with their article: “Echo Therapeutics Announces New Patent for its Non-Invasive Sensing Technology” published on June 22, 2016, Prnewswire.com published: “Echo Therapeutics Announces Significant Progress in Key Development Milestones” on May 03, 2016. More interesting news about Echo Therapeutics Inc (OTCMKTS:ECTE) were released by: Valuewalk.com and their article: “Echo Therapeutics Inc (ECTE) – A Stock With No Revenue And A Short Catalyst” published on June 27, 2016 as well as Prnewswire.com‘s news article titled: “Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive …” with publication date: December 23, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>